RecruitingNCT06031805
PRostate Olaparib Real World Evidence Study
a French Observational Prospective Multicenter Study of Adult Patients Treated in the Real-life Setting With Olaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
Sponsor
AstraZeneca
Enrollment
300 participants
Start Date
Oct 11, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This French non-interventional prospective multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria3
- Adult male patients (≥ 18 years old)
- With metastatic castration-resistant prostate cancer - Who have initiated olaparib within the last two months of study entry, or for whom the decision to be treated with olaparib has been made by their physician
- Who have been informed and are not opposed to this data collection
Exclusion Criteria2
- Patients opposed to the collection of their data
- Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
Locations(65)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06031805
Related Trials
64Cu-GRIP B in Patients With Advanced Malignancies
NCT058885321 location
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT0710301813 locations
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
NCT074760011 location
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
NCT071425511 location
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984164 locations